DELRAY BEACH, Fla., June 26, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Epigenetics Market is projected to grow from about USD 2.22 billion in 2026 to USD 3.92 billion by 2031, at a CAGR of 12.0%.
Browse 630 market data Tables and 61 Figures spread through 487 Pages and in-depth TOC on 'Epigenetics Market - Global Forecast to 2031'
Epigenetics Market Size & Forecast:
- Market Size Available for Years: 2025-2031
- 2026 Market Size: USD 2.22 billion
- 2031 Projected Market Size: USD 3.92 billion
- CAGR (2026-2031): 12.0%
Epigenetics Market Trends & Insights:
- By method, DNA methylation accounted for the largest share of 56.2% of the epigenetics market in 2025.
- By end user, academic & research institutes accounted for the largest share of 45.9% of the epigenetics products market in 2025.
- North America accounted for the largest share of 41.7% of the epigenetics market in 2025.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
The epigenetics market is expanding as pharmaceutical and biotechnology companies, clinical laboratories, CROs, and academic research institutes increasingly adopt epigenomic technologies to support drug discovery, oncology research, precision medicine, biomarker discovery, and translational studies. Epigenetics tools are being used to analyze DNA methylation, histone modifications, chromatin accessibility, chromatin remodeling, and non-coding RNA regulation for understanding gene expression changes, disease progression, therapeutic response, and target identification. Rising demand for high-throughput, reproducible, and genome-wide epigenetic profiling is accelerating the adoption of next-generation sequencing, PCR & qPCR, ChIP-seq, ATAC-seq, bisulfite sequencing, methylation arrays, and mass spectrometry-based workflows. In addition, the growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, AI-enabled data interpretation, and standardized epigenetic assay kits is improving workflow efficiency, data quality, and clinical research applicability, thereby supporting broader market expansion.
By product, the kits & reagents segment held the largest share of the epigenetics market in 2025.
By product, the epigenetics market is segmented into kits & reagents, enzymes, and instruments & accessories. In 2025, kits & reagents accounted for the largest market share. This is primarily due to their recurring use across DNA methylation analysis, histone modification studies, chromatin accessibility assays, ChIP-seq, bisulfite sequencing, ATAC-seq, PCR-based epigenetic assays, and NGS-based epigenomic profiling. Kits & reagents are widely used by pharmaceutical and biotechnology companies, academic research institutes, clinical laboratories, and CROs for sample preparation, library preparation, target enrichment, biomarker discovery, and validation studies. Their high consumption frequency, protocol-specific requirements, and critical role in ensuring assay reproducibility support their dominance in the market. The increasing adoption of precision medicine, cancer epigenetics research, liquid biopsy-based methylation testing, and multi-omics workflows further strengthens demand for kits & reagents in the epigenetics market.
Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=896
By technology, the next-generation sequencing segment held the largest share of the epigenetics market in 2025.
By technology, the epigenetics market is segmented into next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies. In 2025, next-generation sequencing accounted for the largest market share. This is primarily due to its extensive use in DNA methylation profiling, ChIP-seq, ATAC-seq, RNA-based epigenetic analysis, chromatin accessibility studies, and genome-wide epigenomic mapping. NGS enables high-throughput, sensitive, and comprehensive analysis of epigenetic modifications, making it widely adopted across oncology research, biomarker discovery, drug development, precision medicine, and translational studies. Pharmaceutical and biotechnology companies, academic institutes, clinical laboratories, and CROs increasingly rely on NGS-based workflows for large-scale epigenetic profiling and multi-omics integration. The growing demand for liquid biopsy-based methylation biomarkers, single-cell epigenomics, and advanced cancer diagnostics further supports the leading position of the NGS segment in the epigenetics market.
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America held the largest share of the epigenetics market. This is supported by strong biomedical research infrastructure, high adoption of NGS-based epigenomic profiling, significant investment in oncology, precision medicine, and drug discovery research, and the presence of leading pharmaceutical and biotechnology companies, academic institutes, clinical laboratories, and CROs. The growing use of epigenetic technologies in cancer diagnostics, therapeutic target identification, biomarker validation, and multi-omics research continues to drive demand across the region. Ongoing advancements in sequencing platforms, bioinformatics tools, and AI-enabled data interpretation are further supporting market growth in North America.
Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=896
Top Companies in Epigenetics Market:
The Top Companies in Epigenetics Market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Promega Corporation (US), among others.
Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting
Related Reports:
Next-generation Sequencing Market - Global Forecast to 2031
PCR Technologies Market - Global Forecast to 2030
Genomics Market - Global Forecast to 2030
Mass Spectrometry Market - Global Forecast to 2031
Biomarkers Market - Global Forecast to 2030
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/epigenetics-market-worth-3-92-billion-by-2031--marketsandmarkets-302811663.html
